Nexsen Limited has cleared a major FDA regulatory hurdle for its StrepSure rapid Group B Streptococcus test, confirmed a clear 510(k) submission pathway, and secured over A$1.7 million in non-dilutive grants to expand clinical validation and market rollout in Asia-Pacific and neonatal diagnostics.
- FDA Q-Submission confirms 510(k) pathway for StrepSure
- HK$6 million IGNITE grant supports Hong Kong clinical validation and manufacturing
- AU$0.5 million grant funds neonatal Group B Streptococcus diagnostic development
- ISO 13485 Quality Management System certification progressing toward completion
- Cash reserves of A$5.73 million support ongoing R&D and commercial activities
FDA Regulatory Clarity Reduces Approval Risk
Nexsen Limited (ASX:NXN) marked a pivotal step this quarter by securing FDA alignment on its 510(k) regulatory pathway for StrepSure®, its rapid point-of-care Group B Streptococcus (GBS) diagnostic. The FDA's confirmation during a Q-Submission meeting endorses Nexsen's proposed clinical validation approach, incorporating data from both Australian and U.S. sites, effectively de-risking the path to U.S. market authorisation and setting the stage for a submission targeted in Q4 2026. This milestone is crucial given GBS’s role as a leading cause of severe neonatal infections, with current diagnostics hampered by multi-day lab turnaround times.
Clinical data collection is underway at Northern Health in Melbourne, with U.S. clinical site contracts and CRO management anticipated imminently, underpinning the company’s FDA submission timeline. This progress follows Nexsen’s earlier regulatory readiness moves, including the successful completion of its Stage 1 ISO 13485 audit, confirming its Quality Management System supports clinical validation and manufacturing needs Stage 1 ISO 13485 audit.
Strategic Global Rollout Anchored in Asia-Pacific
Parallel to U.S. regulatory efforts, Nexsen has launched a global rollout strategy prioritising early commercial entry into Asia-Pacific markets with clear regulatory frameworks and unmet clinical needs. Hong Kong is the initial commercial entry point, benefiting from the streamlined Medical Device Administrative Control System (MDACS) for in vitro diagnostics and serving as a manufacturing and distribution hub for the region and broader North Asia.
Supporting this, Nexsen secured a HK$6 million (approximately A$1.2 million) IGNITE Grant from the Hong Kong Science and Technology Parks Corporation, funding local clinical validation through hospital networks, product optimisation, and establishment of in-region manufacturing capability. This non-dilutive funding accelerates Nexsen’s capital-efficient advancement toward commercial readiness in Asia-Pacific HK$6 million IGNITE grant. The company is also advancing partnership discussions in Malaysia and India and exploring Africa as a potential market, leveraging global health organisations to support scaled deployment.
Expanding Clinical Applications with Neonatal Diagnostics
Nexsen broadened StrepSure’s clinical scope by securing a $0.5 million Australian Commonwealth grant to develop a neonatal GBS diagnostic. This adaptation targets early- and late-onset neonatal infections, addressing gaps where maternal screening is incomplete or delayed. The neonatal test aims to provide clinicians with rapid bedside results to identify at-risk newborns, potentially reducing serious complications like sepsis and meningitis.
This grant complements the company’s broader strategy of expanding its rapid diagnostic platform beyond maternal care, reflecting Nexsen’s commitment to tackling critical unmet healthcare needs through point-of-care solutions.
Manufacturing Scale-Up and Quality Certification Progress
Nexsen is advancing its manufacturing capabilities with initial production capacity for approximately one million StrepSure devices annually at the Sir Ian Potter Nanobiosensing Facility at RMIT University in Melbourne. Concurrently, the company is establishing manufacturing in Hong Kong to support regional supply and long-term global scale. The upcoming Stage 2 ISO 13485 certification audit is anticipated in early Q3 2026, followed by alignment with the Medical Device Single Audit Program (MDSAP) to streamline multijurisdictional market access.
These infrastructure developments underpin Nexsen’s readiness for commercialisation and regulatory compliance, essential for its planned market entries and ongoing clinical validation activities.
Pipeline Expansion Beyond GBS Diagnostics
Beyond StrepSure, Nexsen is advancing its kidney diagnostics portfolio with RenalSure® and KidneySure®, targeting acute kidney injury and chronic kidney disease; conditions affecting over 850 million people globally. These diagnostics aim to replicate StrepSure’s rapid, lab-grade point-of-care testing, addressing the critical need for faster diagnosis in these underserved markets. The company secured trademarks for these products and continues regulatory planning and R&D to support market entry.
Additional early-stage projects include bovine mastitis diagnostics and biosecurity applications, leveraging Nexsen’s lateral flow and bioreceptor technology platform, indicating a diversified pipeline that could broaden the company’s market reach.
Financial Position and Operational Outlook
Nexsen ended the quarter with A$5.73 million in cash reserves, deploying $1.08 million net of grant receipts primarily on research, development, and commercial activities aligned with its strategic objectives. Management reports expenditure broadly consistent with IPO prospectus forecasts, supplemented by significant grant funding that now totals over A$13 million. Related party payments were disclosed at $265,000, covering director remuneration and legal services on arms-length terms.
Looking ahead, Nexsen plans to activate U.S. clinical sites and commence patient enrolment in the June quarter, continue clinical validation in Hong Kong, and advance manufacturing scale-up and ISO certification. Engagement with payers and reimbursement strategies across multiple jurisdictions, including the U.S., will also be a focus, reflecting a comprehensive approach to market entry and commercialisation FDA 510(k) submission timeline.
Bottom Line?
Nexsen’s regulatory and grant milestones position StrepSure® for a multi-region rollout, but execution on clinical trials and certification timelines will be critical to sustaining momentum.
Questions in the middle?
- Will Nexsen meet its Q4 2026 FDA submission target given pending U.S. clinical site contracts?
- How will the dual manufacturing hubs in Australia and Hong Kong balance supply chain demands?
- What partnerships will Nexsen secure in Malaysia, India, and Africa to translate clinical validation into commercial uptake?